BerGenBio Reports P-II Trial Results of BGB324 (bemcentinib) as 2L Treatment of Non-Small Cell Lung Cancer
Shots:
- The P-II study evaluating bemcentinib (selective AXL kinase inhibitors) + MSD's pembrolizumab (anti-PD-1 therapy) in NSCLC patients
- The results showed long survival benefits and sustained disease control, m-OS (13.0mos.), m-PFS of 6.2mos., DCR (51.1%) & ORR (11.1%), significant improvement in mOS based on AXL tumor proportion score. Patients with AXL TPS > 5 (46% of evaluable patients), m-OS of 14.8mos. vs 9.9 mos. for patients with AXL TPS < 5
- In patients with an AXL TPS > 5, m-PFS (8.7mos. vs 4.6mos. for patients with AXL TPS < 5), ORR was 21.9%, observed m-OS was similar regardless of patient PD-L1 status. The combination therapy was found to be well-tolerated
Ref: PRNewswire | Image: BerGenBio
Related News:- Bergenbio Reports Results of Bemcentinib in P-II (ACCORD2) Study for the Treatment of COVID-19
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
